Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117081 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL14048880 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL14049050 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL4980169 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL4980179 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL31454809 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL7668284 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL9842434 | 0.83 | — | — | |
| SCHEMBL8446237 | 0.83 | — | — | |
| SCHEMBL8446236 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1982985-A2 | Method for manufacturing a purine derivative | Lonza AG (CH) | 2008-10-22 | — | — | EP | claimed |
| EP-1657243-A1 | Procedure for the production of amino alcohols | Lonza AG (CH) | 2006-05-17 | — | — | EP | claimed |
| US-20040142436-A1 | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R,4S)-4-(2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino)-2-cyclopentenyl-1-methanol | BRIEDEN WALTER (CH) | 2004-07-22 | — | — | US | claimed |
| US-6448402-B2 | REDUCTION OF 2-AZABICYCLO(2.2.1)HEPT-5-EN-3-ONE USING METAL HYRIDE | LONZA AG (CH) | 2002-09-10 | — | — | US | claimed |
| US-20020010360-A1 | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4-((2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino)-2-cyclopentenyl-1- methanol | LONZA AG (CH) | 2002-01-24 | — | — | US | claimed |
| EP-0926131-A2 | Process for the preparation of aminoalcohol derivatives and their further transformation zu (1R,4S)-4-((2-amino-6-chlor-5-formamido-4-pyrimidinyl)-amino)-2-cyclopenten-1-methanol | LONZA A.G. (CH) | 1999-06-30 | — | — | EP | claimed |
| US-10385006-B2 | Process for the preparation of amino alcohol derivatives or salts thereof | GRANULES INDIA LIMITED (IN) | 2019-08-20 | — | — | US | disclosed |
| US-20170233329-A1 | PROCESS FOR THE PREPARATION OF AMINO ALCOHOL DERIVATIVES OR SALTS THEREOF | GRANULES INDIA LTD (IN) | 2017-08-17 | — | — | US | disclosed |
| US-8097723-B2 | Process for the preparation of abacavir | ESTEVE QUIMICA, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| US-8097723-B2 | Process for the preparation of abacavir | ESTEVE QUIMICA, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| US-8097723-B2 | Process for the preparation of abacavir | ESTEVE QUIMICA, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| EP-2125814-B1 | PROCESS FOR THE PREPARATION OF ABACAVIR | ESTEVE QUIMICA SA (ES) | 2010-07-14 | — | — | EP | disclosed |
| US-20100041883-A1 | Process for the preparation of abacavir | Esteve Química, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| US-6087501-A | Chloropyrimidine intermediates and processes for their preparation | GLAXO WELLCOME INC. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0741710-B1 | CHLOROPYRIMIDINE INTERMEDIATES | WELLCOME FOUND (GB) | 2000-05-10 | — | — | EP | disclosed |
| EP-0926131-A2 | Process for the preparation of aminoalcohol derivatives and their further transformation zu (1R,4S)-4-((2-amino-6-chlor-5-formamido-4-pyrimidinyl)-amino)-2-cyclopenten-1-methanol | LONZA A.G. (CH) | 1999-06-30 | — | — | EP | disclosed |
| US-5917042-A | Process for the preparation of 2,5-diamino-4,6-dichloropyrimidine | GLAXO WELLCOME INC. (US) | 1999-06-29 | — | — | US | disclosed |
| US-5917041-A | Chloropyrimidine intermediates | GLAXO WELLCOME INC. (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0878548-A2 | Multistep process for the preparation of (1S,4R)- and/or (1R,4S)-4-(2-Amino-6-Chlor-9-H-purin-9-yl)-2-cyclopentene-1-methanol | LONZA AG (CH) | 1998-11-18 | — | — | EP | disclosed |
| WO-1995021161-A1 | CHLOROPYRIMIDE INTERMEDIATES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233329-A1 | PROCESS FOR THE PREPARATION OF AMINO ALCOHOL DERIVATIVES OR SALTS THEREOF | ADH1C, ADH1A, ALDH7A1 | NR1I2 2191/4885ALB 2819/4885PDE4D 1801/4885 |
| US-20100041883-A1 | Process for the preparation of abacavir | CYP4A11, CYP4F11, CYP3A4 | NR1I2 3021/4885ALB 3231/4885PDE4D 582/4885 |
| US-20020010360-A1 | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4-((2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino)-2-cyclopentenyl-1- methanol | AASDHPPT, ALDH7A1, AADAT | NR1I2 1490/4885ALB 2299/4885PDE4D 1001/4885 |
| US-10385006-B2 | Process for the preparation of amino alcohol derivatives or salts thereof | ADH1C, ADH1A, ALDH7A1 | NR1I2 2339/4885ALB 2605/4885PDE4D 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.